Wei-Ping Violet Shen, MD
Office and Contact Information
CHOC Children's Specialists
1201 W La Veta
Orange, CA 92868
phone: (714) 509-8636
fax: (714) 509-4748
map & directions
- Chair, Oncology, CHOC Children's
- Clinical Research Director, Oncology, CHOC Children's
- Oncology, CHOC Children's Specialists
- Clinical Associate Professor of Pediatrics
UC Irvine Medical Center
Physician / Researcher BioClinical Director of the CHOC Research Program, pediatric hematologist/oncologist Violet Shen, M.D. provides expertise in neuro-oncology and new-agent clinical trials. Dr. Shen is board certified in pediatrics and pediatric hematology/oncology. She served a fellowship at Memorial Sloan-Kettering Cancer Center in New York. She completed her residency and internship at Cornell Medical College, North Shore University Hospital in Manhasset and at St. Vincent's Hospital and Medical Center in New York City, respectively. Dr. Shen received her medical training at National Taiwan University in Taipei. She also speaks Chinese. Dr. Shen manages the Neuro Oncology Clinic at CHOC.
- Medical School
National Taiwan University College of Medicine
- Pediatrics Internship
St Vincent's Hospital and Medical Center, NY
- Pediatrics Residency
Cornell Medical College-North Shore University Hospital
- Pediatric Hematology Oncology Fellowship
Cornell Medical College-New York Hospital and Memorial Sloan-Kettering Cancer Center
American Board of Pediatrics
- Pediatric Hematology/Oncology
American Board of Pediatrics
Honors and Awards
- Selected as one of the Top Doctors of Orange County
Orange Coast Magazine, Multiple years
- American Society of Pediatric Hematology-Oncology
- American Society of Clinical Oncology
- Children Oncology Group
- Society of Neurooncology
ResearchDr. Shen is leading the way for CHOC’s cancer research as the principal investigator for the Children’s Oncology Group (COG) studies, the Children’s Cancer Group (CCG) phase I research, and the COG phase I consortium. CHOC Children's Cancer Institute has been designated as a Phase I clinical trial facility by the Children’s Oncology Group (COG), the nation’s predominant clinical trials group for children and young adult patients with cancer. The Cancer Institute is the only hospital in the southwestern United States—and one of only 21 in North America—offering children Phase I clinical trials for new drugs or treatment. This distinction has provided hope for children whose cancers don’t respond to standard treatment and has made it possible for Dr. Shen and her colleagues to have more than 80 open studies.
- Journal of Clinical Oncology
CHOC Articles & Publications
|Cancer Institute Overview
Making a Mark: October 2008
About 10,000 children under the age of 15 will be diagnosed with cancer this year, according to the American Cancer Society....
|COG Selects CHOC For Phase I Studies
Physician Connection: Summer 2008
CHOC has been designated as a Phase I clinical trial facility by the Children's Oncology Group (COG), the nation's predominant clinical trials group for children and young adult patients with cancer. ...
|More than 80 CHOC Children's Doctors Named "Physicians of Excellence"
January 03, 2012
More than 80 CHOC Children's physicians, including specialists and pediatricians, are named "Physicians of Excellence" by the Orange County Medical Association....
|More than 60 CHOC Children’s Doctors Named “Physicians of Excellence”
January 04, 2011
More than 60 CHOC Children’s physicians, including specialists and pediatricians, are featured as "Physicians of Excellence" in the January 2011 issue of Orange Coast magazine. The "Physicians of Exc...
|More than 50 CHOC Children's Doctors Named "Physicians of Excellence"
January 04, 2010
The Orange County Medical Association names more than 50 CHOC doctors "Physicians of Excellence."...
Hijiya N, Gaynon P, Barry E, Silverman L, Thomson B, Chu R, Cooper T, Kadota R, Rytting M, Steinherz P, Shen V, Jeha S, Abichandani R, Carroll WL. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia. 2009 Dec;23(12):2259-64. Epub 2009 Sep 10.
Jeha S, Gaynon PS, Razzouk BI, Franklin J, Kadota R, Shen V, Luchtman-Jones L, Rytting M, Bomgaars LR, Rheingold S, Ritchey K, Albano E, Arceci RJ, Goldman S, Griffin T, Altman A, Gordon B, Steinherz L, Weitman S, Steinherz P. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol. 2006 Apr 20;24(12):1917-23.
Jeha S, Kantarjian H, Irwin D, Shen V, Shenoy S, Blaney S, Camitta B, Pui CH. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia. 2005 Jan;19(1):34-8.
Shen V, Li X, Murdock M, Resnansky L, McCluskey E, Semba C: Recombinant tissue plasminogen activator (Alteplase) for restoration of function to occluded central venous catheters in pediatric patients. J Pediatr Hematol Oncol 25: 38-45, 2003
Marcos Di Pinto, Ph.D., Violet Shen, M.D., Laura McDonald, M.S., Grace Mucci, Ph.D., Julene Schenk, RN,BSN, Tina Templeman RN, Jody Pathare NP, Kristin Hawking : Intellectual Outcome in Bilingual and Monolingual Children with Medulloblastoma , to be presented at the International Symposium on Pediatric Neuro-Oncology (ISPNO), Vienna, Austria.
Van Huynh, Tina Templeman, Violet Shen, “Toxicity profile of Bevacizumab based regimens in the treatment of pediatric malignant brain tumors - a Single Institution’s Experience, to be presented at International Symposium on Pediatric Neuro-Oncology (ISPNO), Vienna, Austria.
A Lee1, C Fanelli1, LA Harrison1, V Shen2, L Gates2, R Wells2, JE Wolff3, JH Garvin1, DJ Yamashiro1,5, MS Cairo1,4,5 Pilot study of the novel chemotherapy regimen of Topotecan, Ifosfamide, and Carboplatin (TIC) in Children with Refractory/Recurrent Solid Tumors, to be presented at the American Society of Clinical Oncology 2010 Meeting.
Nobuko Hijiya, Paul Gaynon, Manuel Fernandez, Lewis Silverman, Blythe Thomson, Roland Chu, Todd Cooper, Richard Kadota, Michael Rytting, Peter Steinherz, Violet Shen, Sima Jeha, Elly Barry, William L. Carroll: Durable Remissions Observed in a Phase I/II Study of Clofarabine in Combination with Etoposide and Cyclophosphamide in Pediatric Patients with Refractory or Relapsed Acute Leukemia. (presented at ASH 2008)
Kadota R, Shen V, Messinger Y: Safety, pharmacokinetics and efficacy of palonosetron in pediatric patients: A multicenter, stratified, double-blind, phase 3, randomized study. Am Soc Clin Oncol 25: No 18S 543s, 2007
Jeha S, Razzouk, M, Rytting M, Gaynon P, Kadoto R, Rheingold S, Luchtman-Jones L, Shen V, Arceci R, Fernandez M, Weitman S, Steinherz P: Phase II trials of Clofarabine in relapsed or refractory pediatric leukemia. Blood 104 (11):196a, 2004
Jeha S, Kantarjian H, Irwin D, Shen V, Shenoy S, Blaney S, Camitta B, Pui CH: Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia. 2005 Jan;19(1):34-8.
Cairo MS, Davenport V, Bessmertny O, Goldman SC, Berg SL, Kreissman SG, Laver J, Shen V, Secola R, van de Ven C, Reaman GH: Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study. Br. J Haematol 128(1):49-58, 2005
Sima Jeha, Bassem Razzouk, Michael Rytting, Paul Gaynon, Richard Kadota, Susan Rheingold, Lori Luchtman-Jones, Violet Shen, Robert Arcecci. Manuel Fernandez, Steve Weitman, Peter Steinherz: Phase II trials of Clofarabine in relapsed or refractory pediatric leukemia. Blood 104, No 11: 196A,2004
Anderson, P/M., Meyers, P, Kleinerman E, Venkatakrishnan, Hughes, D.P, Herzog C, Huh W, Sutphin R, Vyas YM, Shen, V, Warwick A, Yeager N, Oliva C, Wang B, Liu Y, Chou A: Mifamurtide in Metastatic and Recurrent Osteosarcoma: A Patient Access Study with Pharmacokinetic, Pharmacodynamic and Safety Assessments. Pediat r Blood Cancer, Published online in Wiley Online Library 2013
Hijiya N, Gaynon P, Barry E, Silverman L, Thomson B, Chu R, Cooper, T, Kadota R, Rytting M, Steinherz P, Shen V, Jeha S, Abichandani R, Carroll W: A multi-center phase 1 study of Clofarabine, Etoposide and Cyclophosphamide in combination in pediatric p atients with refractory or relapsed acute leukemia. Blood 118:6043-6049, 2011
N Hijiya, P Gaynon, E Barry, L Silverman, B Thomson, R Chu, T Cooper, R Kadota, M Rytting, P Steinherz,V Shen, S Jeha, R Abichandan and WL Carroll: A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia 23, 2259–2264,2009